United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 550 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. xifaxan is indicated for the treatment of travelers’ diarrhea (td) caused by noninvasive strains of escherichia coli in adults and pediatric patients 12 years of age and older. limitations of use xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli [see warnings and precautions (5.1), clinical pharmacology (12.4), clinical studies (14.1)]. xifaxan is indicated for re

United States - English - NLM (National Library of Medicine)

salix pharmaceuticals, inc. - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 200 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. xifaxan is indicated for the treatment of travelers’ diarrhea (td) caused by noninvasive strains of escherichia coli in adults and pediatric patients 12 years of age and older. limitations of use xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli [see warnings and precautions ( 5.1), clinical pharmacology ( 12.4), clinical studies ( 14.1)]. x

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 200 mg -         to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.         xifaxan 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 200 mg -         to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.  when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.         xifaxan 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - rifaximin - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - rifaximin - oral suspension - 20mg/1ml

Kenya - English - Pharmacy and Poisons Board

ferozsons laboratories limited p.o. ferozsons, amangarh, nowshera, pakistan - rifaximin - film-coated tablet - rifaximin 200mg - rifaximin

Kenya - English - Pharmacy and Poisons Board

ferozsons laboratories limited p.o. ferozsons,… ferozsons laboratories limited p.o. ferozsons, - rifaximin - film-coated tablet - rifaximin 550mg - rifaximin

Kenya - English - Pharmacy and Poisons Board

pharmacor ltd. p.o box 14999 - 00800 - rifaximin bp - film-coated tablet - rifaximin 200mg - rifaximin

Kenya - English - Pharmacy and Poisons Board

rifaximin tablets - tablet - rifaximin tablets 550 mg - rifaximin